Dr Reddy’s sells antibiotic manufacturing unit, related assets in Bristol

Dr Reddy's

Hyderabad: Hyderabad-based pharmaceuticals company, Dr Reddy’s Laboratories sold its antibiotic manufacturing facility and related assets in Bristol, Tennessee, US to Neopharma Inc, a wholly owned subsidiary of the UAE’s largest pharmaceutical manufacturer headquartered in Abu Dhabi, Neopharma LLC.

Dr Reddy’s COO Erez Israeli said, “This sale is in line with our stated priority to streamline and optimise our global cost structures and help us focus on other business priorities to drive growth.”

Suresh Nandiraju, COO, Neopharma, said, “This acquisition is synergetic and will strengthen our product portfolio for driving long-term, sustainable growth by leveraging our global presence.”

Dr Reddy's
The facility is dedicated to secondary oral-solid dose penicillin manufacturing and packaging.

The plant and associated facilities focus on manufacturing or packaging amoxicillin-based products, which include semi-synthetic penicillin.

The 3,90,000 square-foot facility is dedicated to secondary oral-solid dose penicillin manufacturing/packaging and includes process packaging, development, printing and warehouse spaces.

A separate 24,000 square-foot plastics processing facility in Bristol is also included in the transaction.

Antibacterial product rights

Dr Reddy’s has terminated the license granted to Armis Biopharma for its investigational antibacterial product DFA-02 for the prophylaxis of surgical site infections (SSIs).

As an outcome of this termination, Dr Reddy’s has regained worldwide rights to the antibacterial product and is currently evaluating its options to take the programme to next stages.

The investigational product is a combination, broad spectrum gel which is being investigated for the prophylaxis of SSIs as an adjunct to conventional preoperative antibiotic prophylaxis. It has been studied in several phase 1 and 2 clinical studies, and has demonstrated clinical efficacy in several key segments of patients who were at high risk of SSIs.

Launches Imatinib Mesylate

The company has launched Imatinib Mesylate tablets, a therapeutic equivalent generic version of Gleevec tablets in the US market approved by the US Food and Drug Administration (US FDA). This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic / myeloproliferative diseases).

The Gleevec brand and generic sales in the US stood at $868 million for the one year ending July 2018 according to IMS Health.

Dr Reddy’s Imatinib Mesylate tablets are available in 100 mg 30 count bottle size and 400 mg 90 count bottle size.